As investors’ attention turns to the Asco meeting and Amgen and Mirati’s efforts to target the oncogene KRAS, Astrazeneca today revealed that its own first attempt to hit this apparently “undruggable” target had come to nought.
AZD4785, an anti-KRAS antisense oligonucleotide licensed from Ionis back in 2012, has been discontinued, Astra said in its first-quarter earnings call. “We had better programmes to invest in, and we’re still very much committed to KRAS as a target; we’re going at it through other approaches,” it told Vantage today.
Mirati bulls will take some heart from this, given that it suggests that Astrazeneca’s problem was mechanistic rather than target-related. Mirati’s MRTX1257, just like Amgen’s AMG 510, is a small-molecule inhibitor that takes advantage of a hidden groove in the KRAS G12C mutated protein that might be hit with optimal potency.
Work is still early, but AMG 510 appears to be in the lead, with Amgen at Asco set to present results on a few subjects treated in phase I, having already stated that it was looking for best-in-class activity (Asco 2019 – not a Marker of excellence, April 18, 2019).
Apart from the mechanism, a key difference was that the Amgen and Mirati projects hit mutated KRAS, while Astra/Ionis’s AZD4785 targeted the protein regardless of its mutation status. AZD4785 (previously known under the code IONIS-KRAS-2.5 Rx) had just completed its first phase I trial, but came up short.
“The molecule was safe and well tolerated,” Mene Pangalos, Astra’s vice-president of biopharmaceutical R&D, said in response to a question on this morning’s press call. “It didn’t demonstrate sufficient KRAS lowering in terms of target engagement to warrant moving it forward.”
The thinking behind the approach was that an antisense oligonucleotide complementary to a sequence in KRAS mRNA could target mutant and wild-type KRAS isoforms for degradation. A 2017 paper described preclinical data showing target knockdown after subcutaneous delivery.
The Astra/Ionis tie-up dates back to a 2012 preclinical collaboration, and in 2016 resulted in a $28m payment from the UK company when IND-enabling studies were completed. Other approaches to hitting KRAS include an engineered T-cell receptor therapeutic originated by the NCI, licensed to Kite Pharma and now in the hands of Gilead.
|Selected projects against cancers harbouring KRAS mutations|
|AMG 510||Amgen/Carmot Therapeutics||KRAS G12C inhibitor||1st in human data possible at Asco||NCT03600883|
|TNO155||Novartis||SHP2 inhibitor||Study in KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mut tumours||NCT03114319|
|MRTX849||Mirati (ex Array)||KRAS G12C inhibitor||Trial in KRAS G12C mut cancers started Jan 2019||NCT03785249|
|KRAS TCR||Gilead (ex Kite/NCI)||Anti-KRAS G12D engineered T-cell receptor||NCI trial started Apr 2019||NCT03745326|
|AZD4785||Astrazeneca/Ionis||KRAS antisense oligonucleotide||Discontinued after phase I||NCT03101839|
|ARS-1620||Araxes/Johnson & Johnson||KRAS G12C inhibitor||Preclinical||None|
|"Compound B"||Sanofi/X-Chem Pharmaceuticals||KRAS G12C inhibitor||Preclinical||None|
|Unnamed||Boehringer Ingelheim||SOS1 inhibitor||Preclinical||None|
|Unnamed||Mirati||KRAS G12D inhibitor||Preclinical||None|
|MRTX1257||Mirati||KRAS G12C inhibitor||Early pipeline lead||None|
Other oncology discontinuations revealed by Astra today included the PI3k beta/delta inhibitor AZD8186 – logical given the industry’s recent focus on the alpha subtype – and AZD4547, an inhibitor of FGFR, which has generated interest as a targeted approach (Esmo 2018 – Bile duct cancer doctors herald the age of targeted therapy, October 21, 2018).
As for KRAS, Astra has not revealed what other projects it has in development, but work is presumably still very early. The immediate focus remains on Asco and the presentation by Amgen, which claims to have identified a previously unknown pocket induced near KRAS’s G12 cysteine residue.
“We are applying our learnings from G12C to explore other mutations,” Phuong Khanh Morrow, Amgen’s therapy area head of haematology, recently told Vantage.